New CDMO Codis Debuts with Emphasis on Spray Drying Capabilities

Codis, a newly formed contract development and manufacturing organization (CDMO), has emerged as a significant player in the pharmaceutical industry, boasting substantial spray drying capacity and a global workforce. The company, born from the merger of U.S.-based Particle Dynamics and a former EuroAPI facility in the UK, brings together extensive manufacturing capabilities and a wide range of services for pharmaceutical, consumer health, and over-the-counter clients.

Global Footprint and Manufacturing Capacity

Codis has established a strong presence with facilities in multiple locations, including St. Louis and Seymour in the United States, and Haverhill in the UK. The company's combined spray drying output capacity exceeds 5,000 metric tons per year, which it claims is among the largest worldwide. With more than 300 employees across its global operations, Codis has positioned itself as a formidable force in the CDMO landscape.

Nicolas Fortin, Chief Executive of Codis, emphasized the company's strengths, stating, "Codis is built on a foundation of scale, quality, and global reach. With a total of 40,000 square meters of manufacturing space, three GMP facilities and with 7 regulatory approvals achieved, we are uniquely positioned to help pharmaceutical innovators accelerate therapies from development to market."

Comprehensive Service Offerings

Beyond its impressive spray drying capabilities, Codis offers a range of services crucial to drug development and manufacturing. The company is equipped to handle commercial-scale work on:

• Amorphous solid dispersions
• Particle engineering
• Finished dose manufacturing

These offerings cater to a diverse client base across the pharmaceutical, consumer health, and over-the-counter sectors, positioning Codis as a versatile partner in the drug development and manufacturing process.

Strategic Acquisition and Industry Context

The formation of Codis is part of a broader trend of consolidation and specialization in the pharmaceutical manufacturing sector. The UK facility in Haverhill, a key component of Codis' operations, was acquired by Particle Dynamics in June from Paris-based EuroAPI. This acquisition was a strategic move that aligned with EuroAPI's FOCUS-27 restructuring plan, which aims to streamline operations and focus on core production sites across Europe.

The Haverhill site brings with it a notable legacy in pharmaceutical manufacturing, being one of the world's primary producers of sevelamer, a drug used to treat hyperphosphatemia. This established production capability adds significant value to Codis' portfolio and underscores the company's ability to handle specialized, high-volume drug manufacturing.

Codis' debut comes amid a wave of new CDMO launches in 2025, including Rezon Bio in Europe and Meribel Pharma Solutions in the UK, reflecting ongoing dynamism and evolution in the pharmaceutical manufacturing sector.